Orexin Agonists

Orexin agonists are drugs that mimic orexin, a brain neuropeptide the source describes as involved in wakefulness and the boundary between sleep and waking. In Wake-up haul: an Ozempic moment for the brain, Shailesh Chitnis presents them as a possible next major drug class after GLP-1 Agonists, but keeps the broad-use claim early and uncertain.

The first grounded use case is Narcolepsy Wake-Sleep Boundary, with Ovoperextone named as Takeda Pharmaceutical / 武田制药’s drug. The commercial excitement comes from possible future application to depression, ADHD, and addictions, plus market estimates such as Morgan Stanley’s cited 2035 scenario.

Key Claims

• Orexin agonists are framed as wakefulness drugs before they are framed as broad “everything drugs.”
• The Ozempic comparison is an analogy about category expansion, not evidence that orexin will match GLP-1 Agonists in scale or breadth.
• Emmanuel Mignot’s narcolepsy research supplies the source’s discovery bridge from sleep biology to drug development.
• Company interest from Takeda Pharmaceutical / 武田制药, Alkermes, Eli Lilly, and Sentessa Pharmaceuticals turns orexin into a market and M&A story.
• The source explicitly warns that plausible drug ideas often fail before reaching the market.

Connections

• Narcolepsy Wake-Sleep Boundary, Ovoperextone, FDA, and Takeda Pharmaceutical / 武田制药 - first use case and source-described approval context.
• Shailesh Chitnis, Emmanuel Mignot, Alkermes, Eli Lilly, Sentessa Pharmaceuticals, and Morgan Stanley - people, companies, and market signals.
• GLP-1 Agonists, Ozempic, Biotech Capital Cycle, and Clinical Development Capability - analogy and drug-development context.